Publications

Selected peer-reviewed publications, listed in reverse chronological order.

  • Sustainability in medical retina: the environmental impact of using aflibercept 8 mg instead of aflibercept 2 mg in treatment-naïve patients with nAMD. Bowley N, Thomas P, Sivaprasad S, Purbrick RMJ, Beardmore E, Gilbert R, Clarke A, Chase TJG. Eye (Lond). 2025 Dec;39(17):3160–3166. PubMed →
  • Impact of Diabetic Retinopathy on Sleep, Mood, and Quality of Life. Morjaria R, Alexander I, Purbrick RMJ, Safa R, Chong NV, Wulff K, Foster RG, Downes SM; SOMNUS Study Group. Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2304–2310. PubMed →
  • Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors. Purbrick RMJ, Osunkunle OA, Talbot DC, Downes SM. JAMA Oncol. 2017 Feb 1;3(2):275–277. PubMed →
  • Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY). Sivaprasad S, Prevost AT, Vasconcelos JC, et al; CLARITY Study Group. Lancet. 2017 Jun 3;389(10085):2193–2203. PubMed →
  • Direct ophthalmoscopy should be taught to undergraduate medical students — No. Purbrick RM, Chong NV. Eye (Lond). 2015 Aug;29(8):990–1. PubMed →
  • Comparison of Optomap ultrawide-field imaging versus slit-lamp biomicroscopy for assessment of diabetic retinopathy in a real-life clinic. Purbrick RM, Izadi S, Gupta A, Chong NV. Clin Ophthalmol. 2014 Jul 29;8:1413–7. PubMed →
  • Eye disease in older people. Purbrick RMJ, Ah-Chan JJ, Downes SM. Reviews in Clinical Gerontology. 2013 Aug;23(3):234–250. Cambridge Core →
  • Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN study investigators. Lancet. 2013 Oct 12;382(9900):1258–67. PubMed →
  • There is a trend for the diagnosis of glaucoma to be made at an earlier stage in 2010 compared to 2008 in Oxford, United Kingdom. de Silva SR, Riaz Y, Purbrick RM, Salmon JF. Ophthalmic Physiol Opt. 2013 Mar;33(2):179–82. PubMed →
  • Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. IVAN Study Investigators; Chakravarthy U, Harding SP, Rogers CA, et al. Ophthalmology. 2012 Jul;119(7):1399–411. PubMed →
  • Calcification of a Rayner Centerflex 570H hydrophilic acrylic intraocular lens following vitrectomy for retinal detachment: a clinicopathologic report. Purbrick RM, Stavrakas P, Porooshani H, Patel CK, Ferguson DJ. Eur J Ophthalmol. 2010 Nov–Dec;20(6):1082–5. PubMed →
  • The prevalence of patients with ocular genetic disorders attending a general paediatric ophthalmology clinic in the East End of London. Reddy MA, Purbrick R, Petrou P. Eye (Lond). 2009;23(5):1111–4. Full text →
  • The patient's role in the decision-making process — a perspective from the Liverpool Ocular Oncology Centre. Purbrick RM, Tu KL, Damato BE. Eye (Lond). 2006 Sep;20(9):1034–9. PubMed →